Payment overview · 2025
General Payments
$1,313.07
45 reported records · 14 companies
Healthcare provider profile · identity verified
Lisa E Heichberger, MD
Allopathic & Osteopathic Physicians|Family Medicine · MANNING, SC · NPI 1730166430
Verified facts
What the public records show
CMS Open Payments records show Lisa E Heichberger, MD received $1,313.07 in general payments during 2025 across 45 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Entresto, Farxiga, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $275.33 | 21.0% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $174.06 | 13.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.77 | 11.5% | 5 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $148.92 | 11.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $118.84 | 9.1% | 7 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $104.71 | 8.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $98.23 | 7.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.01 | 5.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.72 | 3.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.57 | 2.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.09 | 2.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.34 | 1.9% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $17.45 | 1.3% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.03 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,313.07 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $193.48 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $182.40 | 5 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $148.92 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $148.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $126.74 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $118.84 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $104.71 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $100.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $98.23 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $98.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $69.00 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $69.00 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.65 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.72 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.53 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.48 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.48 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.34 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $6.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 14 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 68 |
| Losartan Potassium | Losartan Potassium | 238 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 229 | 68 |
| Omeprazole | Omeprazole | 227 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 53 |
| Metformin Hcl | Metformin Hcl | 151 | 46 |
| Famotidine | Famotidine | 149 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 37 |
| Gabapentin | Gabapentin | 123 | 41 |
| Potassium Chloride | Potassium Chloride | 122 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 27 |
| Allopurinol | Allopurinol | 114 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 39 |
| Ozempic | Semaglutide | 110 | 23 |
| Alprazolam | Alprazolam | 108 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 35 |
| Tramadol Hcl | Tramadol Hcl | 86 | 18 |
| Irbesartan | Irbesartan | 85 | 20 |
| Carvedilol | Carvedilol | 84 | 21 |
| Montelukast Sodium | Montelukast Sodium | 83 | 22 |
| Eliquis | Apixaban | 82 | 19 |
| Lisinopril | Lisinopril | 82 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 18 |
| Trazodone Hcl | Trazodone Hcl | 71 | 19 |
| Furosemide | Furosemide | 67 | 27 |
| Clonazepam | Clonazepam | 64 | suppressed |
| Simvastatin | Simvastatin | 62 | 18 |
| Metformin Hcl Er | Metformin Hcl | 61 | 22 |
| Farxiga | Dapagliflozin Propanediol | 59 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 13 |
| Lorazepam | Lorazepam | 57 | suppressed |
| Meloxicam | Meloxicam | 56 | 17 |
| Ezetimibe | Ezetimibe | 55 | 17 |
| Mounjaro | Tirzepatide | 53 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 15 |
| Pregabalin | Pregabalin | 51 | 14 |
| Valsartan | Valsartan | 50 | 18 |
| Spironolactone | Spironolactone | 47 | 13 |
| Jardiance | Empagliflozin | 46 | 17 |
| Sertraline Hcl | Sertraline Hcl | 46 | 18 |
| Repatha Sureclick | Evolocumab | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 43 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Celecoxib | Celecoxib | 35 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 11 |
| Valacyclovir | Valacyclovir Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 12 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 11 |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Estradiol | Estradiol | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Fentanyl | Fentanyl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Prednisone | Prednisone | 13 | 11 |
| Brilinta | Ticagrelor | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,313.07 · 45 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, AREXVY, BREZTRI, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, Dexcom G6 Transmitter, ENTRESTO, EVENITY, FARXIGA, FLOWTRIEVER CATHETER, S, JARDIANCE, KRYSTEXXA, LEQVIO, NUPLAZID, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Veozah | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error